


BENZONATATE - benzonatate capsule

Unit Dose Services

DESCRIPTION

Benzonatate, a non-narcotic oral antitussive agent, is 2, 5, 8, 11, 14, 17, 20, 23, 26-nonaoxaoctacosan-28-yl p-(butylamino) benzoate; with a molecular weight of 603.7. Each soft gelatin capsule, for oral administration, contains 100 mg or 200 mg of benzonatate USP. Benzonatate Capsules, USP also contain the following inactive ingredients: D&C Yellow # 10, gelatin, glycerin, purified water, methylparaben, propylparaben and titanium dioxide.



CLINICAL PHARMACOLOGY

Benzonatate acts peripherally by anesthetizing the stretch receptors located in the respiratory passages, lungs, and pleura by dampening their activity and thereby reducing the cough reflex at its source. It begins to act within 15 to 20 minutes and its effect lasts for 3 to 8 hours. Benzonatate has no inhibitory effect on the respiratory center in recommended dosage.

INDICATIONS AND USAGE

Benzonatate is indicated for the symptomatic relief of cough.

CONTRAINDICATIONS

Hypersensitivity to benzonatate or related compounds.

WARNINGS

Severe hypersensitivity reactions (including bronchospasm, laryngospasm and cardiovascular collapse) have been reported which are possibly related to local anesthesia from sucking or chewing the capsule instead of swallowing it. Severe reactions have required intervention with vasopressor agents and supportive measures. **Hypersensitivity**

Isolated instances of bizarre behavior, including mental confusion and visual hallucinations, have also been reported in patients taking benzonatate in combination with other prescribed drugs. **Psychiatric**

Effects

Keep benzonatate capsules out of reach of children. Accidental ingestion of benzonatate resulting in death has been reported in children below age 10. Signs and symptoms of overdose have been reported within 15-20 minutes and death has been reported within one hour of ingestion. If accidental ingestion occurs, seek medical attention immediately (see). **Accidental Ingestion and Death in Children**
OVERDOSAGE

PRECAUTIONS

Benzonatate is chemically related to anesthetic agents of the para-amino-benzoic acid class (e.g. procaine; tetracaine) and has been associated with adverse CNS effects possibly related to a prior sensitivity to related agents or interaction with concomitant medication.

Swallow benzonatate capsules whole. Do not break, chew, dissolve, cut, or crush Benzonatate Capsules. Release of benzonatate from the capsule in the mouth can produce a temporary local anesthesia of the oral mucosa and choking could occur. If numbness or tingling of the tongue, mouth, throat, or face occurs, refrain from oral ingestion of foods or liquids until the numbness has resolved. If the symptoms worsen or persist, seek medical attention. **Information for Patients**

Keep benzonatate out of reach of children. Accidental ingestion resulting in death has been reported in children. Signs and symptoms of overdose have been reported within 15-20 minutes and death has been reported within one hour of ingestion. Signs and symptoms may include restlessness, tremors, convulsions, coma and cardiac arrest. If accidental ingestion occurs, seek medical attention immediately. Overdosage resulting in death may occur in adults. Do not exceed a single dose of 200 mg and a total daily dosage of 600 mg. If you miss a dose of benzonatate capsule, skip that dose and take the next dose at the next scheduled time. Do not take 2 doses of benzonatate at one time.

Usage in Pregnancy

PREGNANCY CATEGORY C

Animal reproduction studies have not been conducted with benzonatate. It is also not known whether benzonatate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Benzonatate should be given to a pregnant woman only if clearly needed.

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk caution should be exercised when benzonatate is administered to a nursing woman.

Nursing Mothers

Carcinogenicity, mutagenicity, and reproduction studies have not been conducted with benzonatate.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Safety and effectiveness in children below the age of 10 have not been established. Accidental ingestion resulting in death has been reported in children below age 10. Keep out of reach of children.

Pediatric Use

ADVERSE REACTIONS

Potential Adverse Reactions to benzonatate may include:

Hypersensitivity reactions including bronchospasm, laryngospasm, cardiovascular collapse possibly related to local anesthesia from chewing or sucking the capsule.

sedation; headache; dizziness; mental confusion; visual hallucinations. **CNS:**

constipation; nausea; GI upset. **GI:**

pruritus; skin eruptions. **Dermatologic:**

nasal congestion; sensation of burning in the eyes; vague “chilly” sensation; numbness of the chest; hypersensitivity. Deliberate or accidental overdose has resulted in death, particularly in children.

Other:

OVERDOSAGE

Intentional and unintentional overdose may result in death, particularly in children. The drug is chemically related to tetracaine and other topical anesthetics and shares various aspects of their pharmacology and toxicology. Drugs of this type are generally well absorbed after ingestion.

The signs and symptoms of overdose of benzonatate have been reported within 15-20 minutes. If capsules are chewed or dissolved in the mouth, oropharyngeal anesthesia will develop rapidly, which may cause choking and airway compromise. CNS stimulation may cause restlessness and tremors which may proceed to clonic convulsions followed by profound CNS depression. Convulsions, coma, cerebral edema and cardiac arrest leading to death have been reported within 1 hour of ingestion. **Signs and Symptoms**

In case of overdose, seek medical attention immediately. Evacuate gastric contents and administer copious amounts of activated charcoal slurry. Even in the conscious patient, cough and gag reflexes may be so depressed as to necessitate special attention to protection against aspiration of gastric contents and orally administered materials. Convulsions should be treated with a short-acting barbiturate given intravenously and carefully titrated for the smallest effective dosage. Intensive support of respiration and cardiovascular-renal function is an essential feature of the treatment of severe intoxication from overdose. Do not use CNS stimulants. **Treatment:**

DOSAGE AND ADMINISTRATION

Adults and Children over 10 years of age: Usual dose is one 100 mg or 200 mg capsule three times a day as needed for cough. If necessary to control cough, up to 600 mg daily in three divided doses may be given. Benzonatate capsules are not to be broken, chewed, dissolved, cut or crushed. **Benzonatate should be swallowed whole.**

BENZONATATE CAPSULE

NDC: 50436-5996-1

BENZONATATE

200 MG

30 CAP

WARNING:

KEEP OUT OF REACH OF CHILDREN
STORE AT 20-25°C (68-77°F)
CONTROLLED ROOM TEMPERATURE



MFG BY: ASCEND LABS

XXXXXXXX

MFG NDC: 67877-0106-05

MFG LOT: XXXXXXXX

LOT: XXXXXXXX EXP: XXXXXXXX

Pkg by: Unit Dose Services, LLC
Miami, FL 33179



NDC: 50436-530 CAP

DRUG: BENZONATATE
200 MG

LOT: XXXXXXXX EXP: XXXXXXXX

NDC: 50436-530 CAP

DRUG: BENZONATATE
200 MG

LOT: XXXXXXXX EXP: XXXXXXXX

NDC: 50436-5996-1

DRUG: BENZONATATE

LOT: XXXXXXXX EXP: XXXXXXXX

NDC: 50436-530 CAP

DRUG: BENZONATATE
200 MG

LOT: XXXXXXXX EXP: XXXXXXXX

BENZONATATE

benzonatate capsule

Product Information

Product Type	HUMAN PRESCRIPTION DRUG LABEL	Item Code (Source)	NDC:50436- 5996(NDC:67877-106)
Route of Administration	ORAL	DEA Schedule	

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
benzonatate (benzonatate)	benzonatate	200 mg

Inactive Ingredients

Ingredient Name	Strength
D&C YELLOW NO. 10	
GELATIN	
GLYCERIN	
WATER	
METHYLPARABEN	
PROPYLPARABEN	
TITANIUM DIOXIDE	

Product Characteristics

Color	yellow	Score	no score
Shape	CAPSULE	Size	19mm
Flavor		Imprint Code	ASC;106
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:50436-5996-1	30 in 1 BOTTLE		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA040749	07/25/2007	

Labeler - Unit Dose Services (831995316)

Registrant - Unit Dose Services (831995316)

Establishment

Name	Address	ID/FEI	Business Operations
Unit Dose Services		831995316	REPACK(50436-5996)

Revised: 6/2012

Unit Dose Services